Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms

Jeffrey Jensen, David F. Archer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Considerable recent interest has focused on new methods of delivery of oral contraceptives that reduce or eliminate the hormone-free interval in order to improve convenience and acceptability, but maintain contraceptive efficacy, minimize side effects and reduce or eliminate the frequency of withdrawal bleeding episodes. Studies in several countries, including the US, have documented that many women would prefer to have no episodes of withdrawal bleeding when using oral contraceptives. This review focuses on a unique oral contraceptive formulation containing levonogestrel 90 μg and ethinyl estradiol 20 μg, approved for use in a continuous dosing regimen designed to eliminate withdrawal bleeding throughout the entire year.

Original languageEnglish (US)
Pages (from-to)319-327
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Oral Contraceptives
Contraception
Hemorrhage
Ethinyl Estradiol
Contraceptive Agents
Hormones
levonorgestrel drug combination ethinyl estradiol

Keywords

  • Amenorrhea
  • Continuous
  • Contraception
  • Extended
  • Levonorgestrel
  • Menstrual symptom

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms. / Jensen, Jeffrey; Archer, David F.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 2, 02.2008, p. 319-327.

Research output: Contribution to journalArticle

@article{73cb38482097478693a2c247f416d5c8,
title = "Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms",
abstract = "Considerable recent interest has focused on new methods of delivery of oral contraceptives that reduce or eliminate the hormone-free interval in order to improve convenience and acceptability, but maintain contraceptive efficacy, minimize side effects and reduce or eliminate the frequency of withdrawal bleeding episodes. Studies in several countries, including the US, have documented that many women would prefer to have no episodes of withdrawal bleeding when using oral contraceptives. This review focuses on a unique oral contraceptive formulation containing levonogestrel 90 μg and ethinyl estradiol 20 μg, approved for use in a continuous dosing regimen designed to eliminate withdrawal bleeding throughout the entire year.",
keywords = "Amenorrhea, Continuous, Contraception, Extended, Levonorgestrel, Menstrual symptom",
author = "Jeffrey Jensen and Archer, {David F.}",
year = "2008",
month = "2",
doi = "10.1517/14656566.9.2.319",
language = "English (US)",
volume = "9",
pages = "319--327",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms

AU - Jensen, Jeffrey

AU - Archer, David F.

PY - 2008/2

Y1 - 2008/2

N2 - Considerable recent interest has focused on new methods of delivery of oral contraceptives that reduce or eliminate the hormone-free interval in order to improve convenience and acceptability, but maintain contraceptive efficacy, minimize side effects and reduce or eliminate the frequency of withdrawal bleeding episodes. Studies in several countries, including the US, have documented that many women would prefer to have no episodes of withdrawal bleeding when using oral contraceptives. This review focuses on a unique oral contraceptive formulation containing levonogestrel 90 μg and ethinyl estradiol 20 μg, approved for use in a continuous dosing regimen designed to eliminate withdrawal bleeding throughout the entire year.

AB - Considerable recent interest has focused on new methods of delivery of oral contraceptives that reduce or eliminate the hormone-free interval in order to improve convenience and acceptability, but maintain contraceptive efficacy, minimize side effects and reduce or eliminate the frequency of withdrawal bleeding episodes. Studies in several countries, including the US, have documented that many women would prefer to have no episodes of withdrawal bleeding when using oral contraceptives. This review focuses on a unique oral contraceptive formulation containing levonogestrel 90 μg and ethinyl estradiol 20 μg, approved for use in a continuous dosing regimen designed to eliminate withdrawal bleeding throughout the entire year.

KW - Amenorrhea

KW - Continuous

KW - Contraception

KW - Extended

KW - Levonorgestrel

KW - Menstrual symptom

UR - http://www.scopus.com/inward/record.url?scp=39049135628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049135628&partnerID=8YFLogxK

U2 - 10.1517/14656566.9.2.319

DO - 10.1517/14656566.9.2.319

M3 - Article

C2 - 18201154

AN - SCOPUS:39049135628

VL - 9

SP - 319

EP - 327

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -